Frequently asked questions about melanotan: answered from the published literature
Compound Basics
What is melanotan?
melanotan refers to two synthetic peptide analogs of alpha-melanocyte-stimulating hormone (alpha-MSH) — Melanotan I (afamelanotide) and Melanotan II — developed at the University of Arizona to study melanogenesis and photoprotection. Both bind melanocortin receptors to trigger eumelanin synthesis and other biological effects depending on which receptor subtype is activated [1][2].
What is the difference between Melanotan I and Melanotan II?
MT-I (afamelanotide) is a linear 13-amino-acid analog with high MC1R selectivity; MT-II is a cyclic 7-amino-acid analog with broader MC1R/MC4R/MC3R activity, conferring additional effects on sexual function and appetite not seen with MT-I. MT-I is EU/FDA-approved for erythropoietic protoporphyria; MT-II has no approved indication [2].
Where are melanotan injections derived from or made out of?
Both analogs are fully synthetic peptides — not derived from biological sources. They were designed computationally at the University of Arizona as truncated, cyclized versions of the endogenous alpha-MSH tridecapeptide and are manufactured via solid-phase peptide synthesis from standard amino acid precursors [1].
What is melanotan 2 used for in research?
Published research has investigated MT-II across four domains: pigmentation and melanogenesis (photoprotection model, Phase I data [3]), erectile dysfunction (MC4R-mediated erection studies in psychogenic and organic ED [5][6][7]), appetite and metabolism (MC4R anorexigenic effects in rodent ICV models [8][9][10]), and peripheral nerve regeneration (subcutaneous MT-II in rat sciatic crush and cisplatin neuropathy models [21]).
Mechanism and Pharmacology
How does melanotan work in the body?
Both analogs bind melanocortin receptors on melanocytes, triggering eumelanin production via the cAMP/PKA/CREB/MITF/tyrosinase cascade [4]. MT-II's additional MC4R binding accounts for its effects on appetite (paraventricular nucleus, nucleus accumbens) and penile erection (NO-mediated cavernosal signaling) observed in rodent and early human studies [5][8].
Does melanotan work without sun exposure?
Phase I data (Dorr et al. 1996) showed measurable pigmentation increases without UV in 2 of 3 subjects [3]. MT-II activates MC1R directly, bypassing the UV-induced keratinocyte pathway. Subsequent observations suggest minimal UV can accelerate the response, but the peptide alone stimulates baseline eumelanin production without UV.
Does Melanotan 2 make your hair darker?
Hair darkening has been reported in case reports and anecdotal accounts. MC1R is expressed in hair follicle melanocytes, and its activation preferentially increases eumelanin — the mechanistic basis is plausible. Controlled peer-reviewed clinical study data on MT-II-induced hair color change in humans has not been identified in the published literature.
Does melanotan cause fat loss?
Rodent central infusion studies demonstrated anorexic effects and adiposity reduction via MC4R. Chronic central MTII over 40 days reduced intra-abdominal fat 35–55% in aged rats, with a 3-fold increase in brown adipose tissue thermogenic capacity [9]. Tolerance to the anorexic effect developed within 5 days in a Zucker rat model, but adiposity reduction was sustained [8]. No controlled human data on weight or fat-mass reduction from MT-II exists.
Safety and Adverse Events
Does Melanotan 2 affect the kidneys?
Two published case reports document renal adverse events. In one, 27 mg cumulative MT-II over 6 months produced renal infarction affecting ~50% of the kidney in a 45-year-old male [11]. In another, a single 6 mg injection produced rhabdomyolysis (CPK 17,773 IU/L) and acute kidney injury requiring 3-day ICU admission in a 39-year-old man [12]. Both cases involved doses substantially above Phase I study ranges.
Can melanotan affect the appearance of moles?
Darkening and new appearance of melanocytic nevi has been documented in published case reports [13][14] and regulatory safety notices (HPRA, TGA). Mechanism: increased MC1R stimulation in nevi-associated melanocytes. A 25-year-old developed dysplastic nevi with severe dysplasia on histopathology; a 16-year-old with FAMMM syndrome developed multiple dark nevi that partially reversed after cessation [14].
Is melanotan (afamelanotide) or Melanotan II truly dangerous?
MT-I (afamelanotide/Scenesse) has an established safety record in regulated clinical trials for EPP — 1,023 implants over 8 years with only minor adverse events [16]. MT-II lacks the same regulatory review. Case reports document nausea [3], priapism [5], mole changes [13][14], renal infarction [11], rhabdomyolysis with AKI [12], and mucosal malignant melanoma associated with nasal spray use [25]. Human controlled safety data covers only small Phase I trials.
What are the nausea and flushing effects seen in melanotan research?
Nausea, facial flushing, and fatigue were the most commonly reported adverse events in Phase I trials and observational case series. Effects were generally dose-dependent and transient in controlled studies [3][5][6]. The mechanistic basis is central MC4R activation driving oxytocin neuronal firing in hypothalamic nuclei [26]. The 2021 qualitative forum study of 205 users confirmed nausea and flushing as predominant adverse themes [23].
Does Melanotan 2 lower testosterone?
No controlled trial data on testosterone suppression exists for MT-II. A rat co-infusion study found that MT-II did not affect NPY-driven suppression of the gonadotropic axis (LH) or somatotropic axis (GH) [22]. MT-II's pro-erectile signaling operates via central MC4R, not gonadal androgen pathways. Testosterone was not a measured endpoint in any published MT-II human trial.
Is melanotan peptide safe to use?
MT-I (afamelanotide/Scenesse) is EU/FDA-approved for EPP with an established safety record. MT-II has no approved indication; regulatory bodies (FDA, TGA, HPRA, MHRA) classify it as an unapproved substance. Human safety data is limited to small Phase I trials (3–20 subjects). Case reports of serious adverse events from self-administered uncontrolled use are documented in the published literature [11][12][13][25].
Duration and Dosing
How long does tan from melanotan last?
In the Dorr 1996 Phase I trial, pigmentation increases were still measurable 4–6 weeks after the last dose; duration was variable and correlated with baseline Fitzpatrick skin type [3]. Melanin synthesis continues after rapid peptide clearance, producing the observed persistence.
Does melanotan permanently tan skin?
Research does not support permanent pigmentation. The 2012 Sivyer case report noted skin color paling three months after cessation [14]; the 2026 Bonchev oral mucosa case showed partial reversal by 28 days post-cessation [24]. Ongoing UV exposure or re-dosing appears required to maintain elevated pigment levels.
How long does it take for melanotan to start working?
In Phase I trials, objective colorimetric pigmentation increases were measurable at 2–4 weeks of daily subcutaneous dosing [3]. Subjective tanning was reported by participants within the first week, though objective colorimetry showed slower change. ED effects in the Wessells trials were observed acutely within hours of a single injection [5].
How long does melanotan last?
Phase I data suggests pigmentation persists 4–6 weeks post-cessation [3]. The compound's plasma half-life in rats is biphasic and rapid after IV administration [18]; MT-I's beta half-life in humans is 0.8–1.7 hours subcutaneous [17]. Erectogenic effect duration in Phase I subjects: approximately 38–45 minutes at >80% rigidity [5][7].
How to reconstitute melanotan 2 for research?
Laboratory protocols typically reconstitute lyophilized MT-II with bacteriostatic water at 1–2 mg/mL concentrations. Reconstituted solutions are stored at 4°C and used within published study timeframes per institutional protocols. The cyclic structure provides greater enzymatic resistance than linear alpha-MSH, but standard cold-chain peptide handling applies.
Melanotan II vs. PT-141: What Is the Relationship?
PT-141 (bremelanotide) is a direct chemical descendant of MT-II, developed by Palatin Technologies. It retains MT-II's cyclic heptapeptide scaffold with modifications that concentrate activity at MC4R and reduce MC1R (pigmentation) activity. The intent: preserve the erectogenic and libido-enhancing effects documented in MT-II Phase I trials while minimizing tanning as a side effect.
PT-141 received FDA approval in June 2019 as bremelanotide (FDA-approved) — 1.75 mg subcutaneous — for hypoactive sexual desire disorder in premenopausal women. It is the first FDA-approved compound derived from the Arizona melanocortin research program [19]. The relationship: MT-II → Melanotan II vs. PT-141 → bremelanotide is a direct translational chain in which each step refined receptor selectivity.
MT-II itself has no FDA-approved indication. The approval of its derivative does not change MT-II's regulatory status.